Edwards Lifesciences Corporation (NYSE:EW) Shares Sold by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd cut its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 42.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,543,428 shares of the medical research company's stock after selling 1,125,415 shares during the quarter. AustralianSuper Pty Ltd owned approximately 0.26% of Edwards Lifesciences worth $111,868,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Edwards Lifesciences by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock valued at $5,117,845,000 after purchasing an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Edwards Lifesciences by 5.3% during the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock valued at $2,458,601,000 after purchasing an additional 1,678,154 shares in the last quarter. Geode Capital Management LLC grew its position in Edwards Lifesciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock worth $1,007,520,000 after acquiring an additional 126,194 shares in the last quarter. Jennison Associates LLC grew its position in Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock worth $731,036,000 after acquiring an additional 2,576,383 shares in the last quarter. Finally, Norges Bank purchased a new position in Edwards Lifesciences in the fourth quarter worth about $610,895,000. 79.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

EW has been the subject of several recent research reports. Canaccord Genuity Group lifted their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research report on Friday, April 25th. Wall Street Zen lowered Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Friday, May 16th. Robert W. Baird lifted their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research report on Thursday, April 24th. Evercore ISI lifted their price target on Edwards Lifesciences from $73.00 to $77.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Finally, Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of "Hold" and a consensus price target of $81.00.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the sale, the insider directly owned 206,900 shares of the company's stock, valued at approximately $15,565,087. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bernard J. Zovighian sold 5,980 shares of the company's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $74.91, for a total transaction of $447,961.80. Following the completion of the sale, the chief executive officer directly owned 58,284 shares in the company, valued at approximately $4,366,054.44. The trade was a 9.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,848 shares of company stock valued at $2,314,488 in the last 90 days. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

Shares of EW traded down $0.13 during trading hours on Tuesday, reaching $76.43. 1,212,411 shares of the company traded hands, compared to its average volume of 5,258,942. The stock has a market capitalization of $44.83 billion, a P/E ratio of 10.91, a P/E/G ratio of 3.84 and a beta of 1.11. The company has a quick ratio of 3.66, a current ratio of 4.45 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $58.93 and a 12-month high of $88.50. The business has a fifty day moving average price of $76.50 and a 200-day moving average price of $73.44.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The firm had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period in the previous year, the company earned $0.66 earnings per share. The business's quarterly revenue was up 6.2% compared to the same quarter last year. Equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.